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ABSTRACT
The benzylindazole derivative 3-(5!-hydroxymethyl-2!-furyl)-1-
benzyl indazole (YC-1) is an allosteric stimulator of soluble
guanylate cyclase (sGC) that sensitizes the enzyme to the gas-
eous ligands carbon monoxide (CO) and nitric oxide (NO). In
this study, we examined whether YC-1 also promotes the pro-
duction of these gaseous monoxides by stimulating the expres-
sion of the inducible isoforms of heme oxygenase (HO-1) and
NO synthase (iNOS) in vascular smooth muscle cells (SMCs).
YC-1 increased HO-1 mRNA, protein, and promoter activity
and potentiated cytokine-mediated expression of iNOS protein
and NO synthesis by SMCs. The induction of HO-1 by YC-1
was unchanged by the sGC inhibitor, 1H-(1,2,4)oxadiazolo[4,3-
!]quinozalin-1-one (ODQ) or by the protein kinase G inhibitors
(8R,9S,11S)-(")-2-methyl-9-methoxyl-9-methoxycarbonyl-8-
methyl-2,3,9,10-tetrahydro-8,11-epoxy-1H,8H,11H-2,7b,11a-
triazadibenzo(a,g)cyclocta9(cde)trinen-1-one (KT 5823) and
YGRKKRRQRRRPPLRKKKKKH-amide (DT-2) and was not dupli-
cated by 8-bromo-cGMP or the NO-independent sGC stimulator
5-cyclopropyl-2[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b] pyridine-
3-yl] pyrimidin-4-ylamine (BAY 41-2272). However, the YC-1-
mediated induction of HO-1 was inhibited by the phosphatidyl-
inositol-3-kinase (PI3K) inhibitors wortmannin and 2-(4-
morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride
(LY294002). In contrast, the enhancement of cytokine-stimu-
lated iNOS expression and NO production by YC-1 was pre-
vented by ODQ and the protein kinase A inhibitor (9S,10S,
12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,
12-epoxy-1H-diindolo(1,2,3-fg:3!,2!,1!-kl)pyrrolo(3,4-i)(1,6)-
benzodiazocine-10-carboxylic acid hexyl ester (KT 5720) and
was mimicked by 8-bromo-cGMP and BAY 41-2272. In con-
clusion, these studies demonstrate that YC-1 stimulates the
expression of HO-1 and iNOS in vascular SMCs via the PI3K
and sGC-cGMP-protein kinase A pathway, respectively. The
ability of YC-1 to sensitize sGC to gaseous monoxides and
simultaneously stimulate their production through the induction
of HO-1 and iNOS provides a potent mechanism by which the
cGMP-dependent and -independent biological actions of this
agent are amplified.
The benzylindazole derivative 3-(5!-hydroxymethyl-2!-
furyl)-1-benzyl indazole (YC-1) is a nitric oxide (NO)-indepen-
dent allosteric stimulator of soluble guanylate cyclase (sGC)
that elevates intracellular cGMP levels in diverse tissues,
including platelets, blood vessels, and vascular endothelial
and smooth muscle cells (SMCs) (Ko et al., 1994; Friebe et al.,
1996; Mulsch et al., 1997; Friebe and Koesling, 1998; Tulis et
al., 2000; Schmidt et al., 2001; Tulis et al., 2002). YC-1
activates sGC by stabilizing the active configuration of the
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enzyme and increasing the affinity of sGC for substrate GTP
(Friebe et al., 1996; Friebe and Koesling, 1998; Lee et al.,
2000). Activation of sGC by YC-1 is crucially dependent on
the presence of the reduced prosthetic heme moiety of the
enzyme because its removal or oxidation virtually abolishes
YC-1-induced sGC activation (Freibe and Koesling, 1998). It
is interesting that YC-1 enhances sGC activation by the
ligands NO and carbon monoxide (CO) through stabilization
of the active enzyme configuration and by decreasing the
dissociation rates of these gases from the activated enzyme
(Friebe and Koesling, 1998; Russwurm et al., 2002). It is
remarkable that YC-1 converts the relatively weak sGC ac-
tivator CO to a potent activator whose effectiveness is com-
parable with that of NO (Friebe et al., 1996; Stone and
Marletta, 1998).
Vascular SMCs generate CO and NO via the heme oxygen-
ase (HO) and NO synthase enzymes, respectively. HO oxida-
tively degrades heme to yield equimolar amounts of CO,
biliverdin, and iron. Two distinct isoforms of HO, HO-1 and
HO-2, have been identified in vascular SMCs (Wu and Wang,
2005; Durante et al., 2006). Although HO-2 is primarily
expressed constitutively, HO-1 is a highly inducible isoform
that is up-regulated by a number of biochemical and bio-
physical stimuli. Induction of HO-1 elicits potent antiprolif-
erative, anti-inflammatory, antithrombotic, and antioxidant
effects in the circulation via the generation of CO and bi-
liverdin. On the other hand, the predominant source of NO
formation by vascular SMCs is via the metabolism of
L-arginine by inducible NO synthase (iNOS). The iNOS iso-
form is expressed after stimulation with inflammatory medi-
ators and generates large amounts of NO over a prolonged
period of time. In addition to reducing vasomotor tone and
platelet aggregation, the generation of NO by vascular SMCs
limits intimal thickening at sites of vascular injury by block-
ing SMC proliferation and migration (Kibbe et al., 1999).
YC-1 represents the prototype of an important novel class
of NO-independent stimulators of sGC that exhibit therapeu-
tic potential for the treatment of a range of vascular diseases,
including hypertension, thrombosis, erectile dysfunction,
and postangioplasty restenosis (Tulis, 2004; Evgenov et al.,
2006). In this respect, YC-1 inhibits platelet aggregation and
thrombosis in various experimental models (Teng et al.,
1997). In addition, YC-1 lowers blood pressure and dilates
blood vessels in normotensive and hypertensive animals
(Rothermund et al., 2000). Furthermore, studies from our
laboratories and others found that YC-1 inhibits vascular
SMC proliferation and neointima formation after balloon
injury of rat carotid arteries (Tulis et al., 2000, 2002; Wu et
al., 2004; Liu et al., 2006). Moreover, YC-1 markedly en-
hances the antiaggregatory and vasodilator potency of NO
and CO (Freibe et al., 1998; McLaughlin et al., 2000; Rother-
mund et al., 2000; Motterlini et al., 2005).
Although YC-1 has been shown to potentiate the biolog-
ical actions of NO and CO by sensitizing sGC to these
gaseous monoxides, the ability of YC-1 to influence the
production of these gases has not been fully investigated.
In the present study, we investigated the role of YC-1 in
regulating HO and iNOS expression in vascular SMCs. In
addition, we identified signaling pathways by which YC-1
modulates the expression of these gas-generating en-
zymes. The ability of YC-1 to coordinately stimulate the
expression of enzymes responsible for generating diatomic
gases and sensitize sGC to these gaseous ligands may
provide a novel mechanism by which this agent is able to
amplify increases in tissue cGMP and promote its benefi-
cial effects in the circulation. In addition, the induction of
HO-1 and iNOS by YC-1 may contribute to the versatile
pharmacological profile of this promising therapeutic
compound.
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Fig. 1. YC-1 stimulates HO-1 protein expression in vascular SMCs. A,
concentration-dependent effect of YC-1 (5–100 "M for 24 h) on HO-1 and
HO-2 protein expression. B, time course of HO-1 and HO-2 protein
expression after the administration of YC-1 (100 "M). C, BAY 41-2272
(5–100 "M for 24 h) fails to stimulate HO-1 protein expression. HO-1 and
HO-2 protein levels are expressed in arbitrary units (a.u.). Results are
means # S.E.M. of three to four experiments. !, statistically significant
effect of YC-1.
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Materials and Methods
Materials. Streptomycin, penicillin SDS, cycloheximide, actino-
mycin D, trypsin-EDTA, TES, HEPES, collagenase, elastase, glu-
tamine, glycerol, bromphenol blue, 8-bromo-cGMP, BAY 41-2272,
DT-2, 3-isobutyl-1-methylxanthine, naphthyl ethylenediamine dihy-
drochloride, curcumin, sulfanilamide, and minimum essential me-
dium were from Sigma-Aldrich (St. Louis, MO); 1H-(1,2,4)oxadia-
zolo[4,3-!]quinozalin-1-one (ODQ), KT-5823, KT-5270, wortmannin,
LY294002, U0125, PD98059, SB203580, and SP600125 were from
Calbiochem-Novabiochem (San Diego, CA); interleukin-1# was from
R&D Systems (Minneapolis, MN); tumor necrosis factor-! was
from Genzyme (Boston, MA); polyclonal HO-1 and HO-2 antibodies
were from Nventa Biopharmaceuticals (Victoria, BC, Canada); a
polyclonal iNOS antibody was from BD Biosciences (San Jose, CA); a
polyclonal antibody against #-actin was from Santa Cruz Biotech-
nologies (Santa Cruz, CA); antibodies against phospho-ERK1/2,
phospho-p38 mitogen-activated protein kinase (MAPK), phospho-
JNK, and phospho-Akt were from Cell Signaling Technology (Dan-
vers, MA); and [32P]dCTP (3000 Ci/mmol) was from GE Healthcare
(Chalfont St. Giles, Buckinghamshire, UK).
Cell Culture. Vascular SMCs were isolated by collagenase and
elastase digestion of rat thoracic aortas and characterized by mor-
phological and immunological criteria, as we described previously
(Durante et al., 1993). Cells were cultured serially (passage 3–12) in
minimum essential media supplemented with 10% bovine serum, 2
mM L-glutamine, 5 mM TES, 5 mM HEPES, 100U/ml penicillin, and
100U/ml streptomycin and incubated in an atmosphere of 95%
air/5% CO2.
Western Blotting. Cells were lysed in sample buffer (125 mM
Tris, pH 6.8, 12.5% glycerol, 2% SDS, 50 mM sodium fluoride, and
trace bromphenol blue), and proteins were separated by SDS-poly-
acrylamide gel electrophoresis. After transfer to nitrocellulose mem-
brane, blots were blocked with phosphate-buffered saline and nonfat
milk (5%) and then incubated with antibodies directed against HO-1
(1:1500), HO-2 (1:500), iNOS (1:2000), phospho-ERK1/2 (1:1000),
phospho-p38 MAPK (1:500), phospho-JNK (1:1000), phospho-Akt (1:
1000), or #-actin (1:2000). Membranes were washed in phosphate-
buffered saline, incubated with horseradish peroxidase-conjugated goat
anti-rabbit, rabbit anti-mouse, or donkey anti-goat antibody, and devel-
oped with commercial chemoluminescence reagents (GE Healthcare).
The expression of HO-1 and HO-2 protein was quantified by scanning
densitometry and normalized with respect to #-actin.
HO-1 mRNA Expression. HO-1 mRNA levels were determined
by Northern blotting. Total RNA (30 "g) was loaded onto 1.2%
agarose gels, fractionated by electrophoresis, and blots were trans-
ferred to Gene Screen Plus membranes (PerkinElmer Life and Ana-
lytical Sciences, Waltham, MA). Membranes were prehybridized for
4 h at 68°C at in rapid hybridization buffer (GE Healthcare) and then
incubated overnight at 68°C in hybridization buffer containing
[32P]DNA probes (1 $ 108 cpm) for HO-1 or 18S rRNA. DNA probes
were generated by reverse-transcriptase polymerase chain reaction
and labeled with [32P]dCTP using a random priming kit (GE Health-
care). After hybridization, membranes were washed, exposed to
X-ray film at "70°C, and HO-1 expression was quantified by scan-
ning densitometry and normalized with respect to 18S rRNA.
A B
C
YC-1 (50µM)
HO-1
0     2    4    8   24   hours
18S RNA
Time (hours)
0 2 4 8 24
H
O
-1
 m
R
N
A
 (
a.
u
.)
0
1
2
3
∗
∗
∗
∗
18S RNA
HO-1
co
nt
ro
l
YC
-1
YC
-1
 +
 A
ct
D
YC
-1
 +
 C
X
YC-1  YC-1  YC-1
H
O
-1
 m
R
N
A
 (
a.
u
.)
0
1
2
3
4
∗
∗
--
ActD CX
++
10 50 100
L
u
ci
fe
ra
se
 A
ct
iv
it
y
(f
o
ld
 in
d
u
ct
io
n
)
0
1
2
3
∗
YC-1 (µM)
∗
0   5   10  20  50  100
HO-1
18S RNA
YC-1 (µM)
0 5 10 20 50 100
H
O
-1
 m
R
N
A
 (
a.
u
.)
0
2
4
6
8
10
12
∗
∗
∗
YC-1 (µM)
D
Fig. 2. YC-1 stimulates HO-1 mRNA expres-
sion and promoter activity in vascular SMCs.
A, time course of HO-1 mRNA expression
after the administration of YC-1 (50 "M). B,
concentration-dependent increase in HO-1
mRNA after the administration of YC-1 (5–
100 "M for 24 h). C, effect of actinomycin D
(ActD; 2 "g/ml) and cycloheximide (CX; 5 "g/
ml) on YC-1 (50 "M for 8 h)-mediated in-
crease in HO-1 mRNA. D, effect of YC-1 (10–
100 "M for 24 h) on HO-1 promoter activity.
HO-1 mRNA expression is expressed in arbi-
trary units (a.u.). Results are means #
S.E.M. of three to five experiments. !, statis-
tically significant effect of YC-1.
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HO-1 Promoter Analysis. HO-1 promoter activity was deter-
mined using a full-length murine HO-1 promoter/firefly luciferase
construct that was generously provided by Dr. Jawed Alam (Ochsner
Clinic Foundation, New Orleans, LA). The HO-1 promoter (1 "g/ml)
and pCMV#gal (1 "g/ml) were transfected into SMCs using Lipo-
fectamine, cultured for 24 h, and then treated with YC-1. Cells were
collected, lysed, and luciferase activity was measured using a lucif-
erase assay system and a GloMax luminometer (Promega, Madison,
WI). Luciferase activity was normalized with respect to #-galactosi-
dase activity (Liu et al., 2007).
MAPK and PI3K Activation. MAPK and PI3K activity were
determined by Western blotting using phospho-specific antibodies,
as we described previously (Liu et al., 2007).
cGMP Assay. Vascular SMCs were pretreated with 3-isobutyl-1-
methylxanthine (0.5 mM) for 30 min and then treated with YC-1 or
BAY 41-2272. In some instances, cells were also pretreated with
ODQ (30 "M) for 30 min before the addition of YC-1. Cells were lysed
using 0.1 M HCl, and cGMP concentrations were measured using a
commercially available kit (Molecular Devices, Sunnyvale, CA).
NO Synthesis. NO synthesis was assessed by measuring the
accumulation of nitrite in the culture media, as we described previ-
ously (Durante et al., 1993). Because NO breaks down to both nitrite
and nitrate, the levels of nitrite in the culture media were deter-
mined after incubation of samples with nitrate reductase to convert
nitrate to nitrite. Samples were then mixed with an equal volume of
Griess reagent (0.1% naphthyl ethylenediamine dihydrochloride and
1% sulfanilamide in 3% H3PO4), incubated at room temperature for
10 min, and absorbance was measured at 540 nm. Concentrations
were determined relative to a standard curve obtained using aque-
ous solutions of nitrite.
Statistics. Results were expressed as the means # S.E.M. Statis-
tical analyses were performed using a Student’s two-tailed t test or
with an analysis of variance with post hoc Bonferroni testing when
multiple groups were compared. P % 0.05 was considered statisti-
cally significant.
Results
Treatment of vascular SMCs with YC-1 (5–100 "M) stim-
ulated a time- and concentration-dependent increase in HO-1
protein. An increase in HO-1 protein was detected after 24 h
with 20 "MYC-1, and higher concentrations of YC-1 resulted
in a progressive increase in HO-1 protein (Fig. 1A). A signif-
icant increase in HO-1 protein was first detected 4 h after
YC-1 exposure and levels remained elevated after 24 h of
treatment (Fig. 1B). In contrast, YC-1 had no effect on HO-2
protein expression (Fig. 1, A and B). It is interesting that
another structurally similar NO-independent sGC stimula-
tor, BAY 41-2272 (5–100 "M), failed to stimulate HO-1 pro-
tein expression (Fig. 1C).
Likewise, the induction of HO-1 protein by YC-1 was asso-
ciated with a time- and concentration-dependent increase in
HO-1 mRNA that preceded the increase in HO-1 protein (Fig.
2, A and B). In addition, incubation of vascular SMCs with
the transcriptional inhibitor actinomycin D (2 "g/ml) com-
pletely blocked the induction of HO-1 mRNA, whereas the
protein synthesis inhibitor cycloheximide (5 "g/ml) only par-
tially inhibited the increase in HO-1 message (Fig. 2C). In
the absence of YC-1, actinomycin D or cycloheximide mini-
mally affected HO-1 mRNA expression (data not shown).
Furthermore, treatment of vascular SMCs with YC-1 (10–
100 "M) for 24 h stimulated a concentration-dependent in-
crease in HO-1 promoter activity (Fig. 2D). To evaluate
whether stabilization of HO-1 mRNA or protein also contrib-
uted to the induction of HO-1, YC-1 (100 "M)-pretreated
SMCs were incubated with actinomycin D (2 "g/ml) or cyclo-
heximide (5 "g/ml) either in the presence or absence of YC-1
(100 "M). However, YC-1 had no effect on the degradation of
HO-1 mRNA or protein (Fig. 3, A and B).
In subsequent experiments we determined the upstream
signaling molecules that mediate the induction of HO-1 by
YC-1. Because YC-1 activates sGC, we first examined whether
cGMP was responsible for triggering HO-1 expression. Treat-
ment of vascular SMCs with YC-1 stimulated the intracellular
accumulation of cGMP, and this was completely blocked by the
sGC inhibitor ODQ (30 "M) (Fig. 4A). Bay 41-2272 (5 "M) also
resulted in a substantial 7-fold increase in intracellular cGMP,
increasing levels from 12 # 4 to 88 # 10 fmol/well. However,
incubation of SMCs with ODQ or the protein kinase G (PKG)
inhibitors KT 5823 (5 "M) or DT-2 (5 "M) failed to prevent the
YC-1-mediated induction of HO-1 protein or mRNA (Fig. 4,
B–D). Moreover, exposure of SMCs to the cGMP lipophilic an-
alog 8-Br-cGMP (5–500 "M) had no effect on HO-1 protein
expression (Fig. 4E).
Treatment of vascular SMCs with YC-1 resulted in the
rapid activation of ERK1/2, JNK1, p38 MAPK, and PI3K, as
reflected by the phosphorylation of Akt (Fig. 5A). Activation
of these proteins occurred within 5 min and persisted for 30
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Fig. 3. YC-1 has no effect on HO-1 mRNA or protein stability in vascular
SMCs. A, effect of YC-1 on HO-1 mRNA stability. SMCs were pretreated
with YC-1 (100 "M for 24 h), washed, and then exposed to actinomycin D
(ActD; 2 "g/ml) in the presence or absence of YC-1 (100 "M), and the
decay of HO-1 mRNA was followed over 8 h. B, the effect of YC-1 on HO-1
protein stability. SMCs were pretreated with YC-1 (100 "M for 24 h),
washed, and then exposed to cycloheximide (CX; 5 "g/ml) in the presence
or absence of YC-1 (100 "M), and the decay of HO-1 protein was followed
over 24 h. Results are means # S.E.M. of three to four experiments.
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min after YC-1 exposure. It is interesting that the sGC in-
hibitor ODQ (30 "M), potentiated the YC-1-mediated induc-
tion of ERK1/2 and JNK1 but had no effect on the activation
of p38 MAPK (Fig. 5B), suggesting that YC-1 activates the
three arms of MAPK via different signaling pathways. In
addition, pretreatment of vascular SMCs with the ERK in-
hibitors U0126 (20 "M) or PD98059 (30 "M), the p38 MAPK
inhibitor SB203580 (30 "M), or the JNK inhibitor SP600125
(20 "M) had no effect on the induction of HO-1 protein by
YC-1 (Fig. 5C). In contrast, the PI3K inhibitors wortmannin
(100 nM) and LY294002 (10 "M) blocked the induction of
HO-1 protein and mRNA (Fig. 5, D and E). Control experi-
ments confirmed the effectiveness of each inhibitor for its
respective enzyme (data not shown). Finally, we also exam-
ined the interaction between YC-1 and curcumin, another
known inducer of PI3K activation and HO-1 gene expression
(Pugazhenthi et al., 2007). Although YC-1 and curcumin
were both able to stimulate PI3K activation and HO-1 pro-
tein expression, the combined addition of these two agents
did not lead to further increases in either PI3K activation or
HO-1 protein (Fig. 6, A and B).
Thereafter, we determined whether YC-1 also regulates
the expression of an NO-generating enzyme. Control, un-
treated SMCs produce minimal amounts of nitrite; however,
treatment of cells with a cytokine mixture consisting of in-
terleukin-1# (5 ng/ml) and tumor necrosis factor-! (20 ng/ml)
resulted in a significant accumulation of nitrite in the culture
medium (Fig. 7A). It is interesting that the simultaneous
administration of YC-1 (10–50 "M) potentiated the cytokine-
mediated production of NO from vascular SMCs (Fig. 7A).
The cytokine-mediated production of nitrite was accompa-
nied by the induction of iNOS protein, and iNOS protein
levels were further increased in the presence of YC-1 (Fig.
7B). In the absence of inflammatory cytokines, YC-1 failed to
stimulate nitrite production or iNOS expression (Fig. 7, A
and B). The ability of YC-1 to enhance cytokine-mediated
nitrite synthesis and iNOS protein expression was dependent
on sGC activity because it was prevented by ODQ (Fig. 8, A
and B). In addition, the lipophilic analog of cGMP, 8-bromo-
cGMP (100–500 "M), and BAY 41-2272 (5–20 "M) potenti-
ated the cytokine-mediated increase in nitrite production
(Fig. 9, A and B). Moreover, 8-bromo-cGMP and BAY 41-2272
augmented the induction of iNOS protein by cytokines (Fig.
9C). In the absence of cytokines, 8-bromo-cGMP or BAY
41-2272 minimally affected nitrite production (Fig. 9, A and
B) and failed to induce iNOS protein (data not shown).
In a final series of experiments, we examined the role of
downstream protein kinases in mediating the augmentation
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of nitrite production by YC-1. Treatment of SMCs with the
PKG inhibitor KT 5823 (5 "M) or DT-2 (5 "M) had no effect
on the ability of cytokines to stimulate nitrite formation and
did not prevent the increase in nitrite synthesis by YC-1 (Fig.
10, A and B). In contrast, the protein kinase A (PKA) inhib-
itor KT 5720 (5 "M) blunted the cytokine-mediated increase
in nitrite formation and reversed the ability of YC-1 to ele-
vate cytokine-mediated nitrite production (Fig. 10C). In the
absence of cytokines, KT 5838, DT-2, or KT 5720 failed to
influence basal nitrite synthesis.
Discussion
In the present study, we identified YC-1 as a novel inducer
of HO-1 and iNOS protein expression in vascular SMCs. It is
interesting that the induction of these two enzymes by YC-1
occurs via distinct signaling pathways. Although YC-1 stim-
ulates the expression of HO-1 via the PI3K signaling path-
way, the augmentation of iNOS expression occurs through
the activation of the sGC-cGMP-PKA pathway. This newly
discovered capacity of YC-1 to stimulate the expression of the
enzymes that generate CO and NO in addition to its docu-
mented sGC-sensitizing ability may provide an important
amplification mechanism by which YC-1 is able to elevate
cellular cGMP and regulate SMC function. Moreover, the
induction of the NO and CO systems by YC-1 may also
contribute to its cGMP-independent actions in vascular
tissues.
Treatment of vascular SMCs with YC-1 results in time-
and concentration-dependent increases in HO-1 mRNA and
protein. The induction of HO-1 by YC-1 does not involve
mRNA or protein stabilization and is probably due to the
transcriptional activation of the gene because actinomycin D
completely blocks HO-1 transcript expression. Moreover,
transient luciferase reporter assays demonstrate that YC-1
directly stimulates HO-1 promoter activity. It is interesting
that the degree of the YC-1-mediated induction of HO-1
mRNA or protein is greater than the increase in HO-1 pro-
moter activity. Although the cause for this discrepancy is not
known, it is important to note that promoter activity was
monitored using a murine HO-1 promoter construct, whereas
HO-1 expression was assessed in rat vascular SMCs. Thus,
the variation in magnitude between YC-1-mediated in-
creases in HO-1 promoter activity and expression may reflect
differences in HO-1 promoter regulation between species
(Sikorski et al., 2004).
Because YC-1 stimulates sGC activity in vascular SMCs
(Tulis et al., 2000, 2002; Pan et al., 2004), we initially deter-
mined the involvement of this enzyme in mediating the in-
duction of HO-1. Although treatment of vascular SMCs with
the sGC inhibitor ODQ blocks the YC-1-mediated increase in
cGMP production, ODQ does not prevent the induction of
HO-1. Likewise, the PKG inhibitor KT 5823 failed to prevent
the induction of HO-1 by YC-1. Because KT 5823 may not be
effective in intact cells (Burkhardt et al., 2000), results ob-
tained with this compound were corroborated using the cell-
permeable PKG inhibitory peptide DT-2. However, DT-2 also
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failed to block YC-1-mediated HO-1 expression. In addition,
administration of the cGMP analog 8-bromo-cGMP or the
NO-independent sGC stimulator BAY 41-2272 had no effect
on HO-1 expression. These findings are consistent with pre-
vious work from our laboratory showing that cGMP does not
alter HO-1 gene transcription in vascular SMCs (Liu et al.,
2007). Moreover, these results indicate that the induction of
HO-1 is not a common property of allosteric sGC activators
and may be a unique property of YC-1.
Because MAPK and PI3K have been implicated in the
induction of HO-1 gene expression (Alam and Cook, 2007), we
investigated the role of these kinases in mediating the induc-
tion of HO-1 by YC-1. Although YC-1 activates all three arms
of the MAPK pathway, pharmacological inhibition of ERK,
p38 MAPK, or JNK fails to block the induction of HO-1 by
YC-1. Instead, we found that PI3K activity is necessary for
the YC-1-mediated increase in HO-1 expression. YC-1 mark-
edly increases PI3K activity in vascular SMCs, and pharma-
cological inhibition of PI3K activity blocks the YC-1-medi-
ated induction of HO-1. This finding is in agreement with
other studies demonstrating a key role for PI3K in stimulat-
ing the expression of HO-1 in several cell types, including
vascular SMCs (Lee et al., 2004). It is interesting that YC-1
failed to augment PI3K activation or HO-1 protein expres-
sion by curcumin, suggesting that these two compounds may
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use a common signaling pathway in stimulating PI3K activ-
ity and HO-1 expression.
Aside from stimulating HO-1 expression, YC-1 influences
the expression of an NO-generating enzyme in vascular
SMCs. In particular, whereas YC-1 alone does not directly
stimulate iNOS protein expression and NO synthesis, it sig-
nificantly enhances the induction of iNOS protein and NO
production by a mixture of inflammatory cytokines. In this
case, the potentiation of iNOS expression and NO synthesis
by YC-1 is mediated through the sGC-cGMP pathway be-
cause inhibition of sGC activity by ODQ abolishes the in-
crease in both iNOS protein and NO synthesis. Moreover, a
lipophilic analog of cGMP or sGC activation by BAY 41-2272
duplicates the stimulatory effects of YC-1 on cytokine-stim-
ulated iNOS expression and NO formation. We were sur-
prised to find that the YC-1-mediated increases in iNOS
expression and NO synthesis are not mediated by PKG,
because inhibition of this kinase by KT 5823 or DT-2 fails to
block the stimulatory effect of YC-1 on NO production. Be-
cause YC-1 and cGMP can also activate PKA (Cornwell et al.,
1994), the role of this kinase in promoting NO synthesis was
also examined. Indeed, we found that the PKA inhibitor KT
5720 suppresses the YC-1-mediated increase in NO produc-
tion in cytokine-treated cells. These findings are consistent
with an earlier report showing that PKA is responsible for
the enhancement of cytokine-mediated NO production by
atrial natriuretic peptide in vascular SMCs (Iimura et al.,
1998). Moreover, our finding that KT 5720 diminishes NO
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synthesis after cytokine stimulation is in accordance with
previous work demonstrating a key role for PKA in mediat-
ing the induction of iNOS by cytokines (Boese et al., 1996).
Our finding that YC-1 promotes the induction of iNOS and
NO synthesis in vascular SMCs, complements a previous
study showing that YC-1 stimulates the release of NO by
endothelial NO synthase in endothelial cells (Wohlfart et al.,
1999), further emphasizing the ability of YC-1 to up-regulate
NO production in the vasculature. However, it contrasts with
recent reports showing that YC-1 attenuates lipopolysaccha-
ride-mediated iNOS expression in macrophages and micro-
glia (Hsiao et al., 2004; Lu et al., 2007). The cause for these
divergent results may reflect differences in cell type, culture
conditions, and/or the nature of the inflammatory stimuli.
The ability of YC-1 to stimulate the production of gaseous
monoxides through the induction of HO-1 and iNOS may be
of pharmacological and therapeutic significance. In particu-
lar, up-regulation of CO and NO synthesis would provide an
important long-term mechanism by which YC-1 elevates tis-
sue cGMP levels. Thus, the induction of HO-1 and iNOS may
amplify the many cGMP-dependent actions of YC-1, includ-
ing its antihypertensive, antiaggregatory, antiproliferative,
and antiapoptotic properties (Teng et al., 1997; Rothermund
et al., 2000; Tulis et al., 2000, 2002; Pan et al., 2004; Tulis,
2004). It is interesting that the induction of HO-1 and iNOS
by YC-1 may also underlie the versatile pharmacological
profile of this agent. In this respect, YC-1 has been shown
recently to elicit an antioxidant effect by inhibiting neutro-
phil superoxide production through a cGMP-independent
pathway (Wang et al., 2002). Furthermore, YC-1 has been
reported to exert a cGMP-independent, anti-inflammatory
action in leukocytes and in endotoxemic mice (Pan et al.,
2005). Given that HO-1 evokes potent antioxidant and anti-
inflammatory effects through the generation of biliverdin
and bilirubin (Wu andWang, 2005; Durante et al., 2006), it is
plausible that YC-1 may suppress both oxidative stress and
inflammation through the induction of HO-1. Moreover, the
ability of YC-1 to enhance iNOS-mediated NO synthesis may
further intensify its anti-inflammatory actions, because the
production of NO by iNOS has been shown to promote the
nitrosylation and inactivation of NF-$B, a key transcription
factor involved in the inflammatory cascade (Marshall and
Stamler, 2001; Reynaert et al., 2004).
In conclusion, these studies demonstrate that YC-1 stimu-
lates the expression of HO-1 and iNOS in vascular SMCs via
the PI3K and sGC-cGMP-PKA pathways, respectively. The
ability of YC-1 to stimulate CO and NO production through
the induction of HO-1 and iNOS and to simultaneously sen-
sitize sGC to these diatomic gases may serve to amplify the
cGMP-dependent biological actions of this indazole deriva-
tive. In addition, the induction of HO-1 and iNOS by YC-1
may contribute to the pleiotropic beneficial effects of this
agent in the circulation.
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